Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
BACKGROUND
Craniopharyngioma patients without GH therapy are at an increased cardiovascular disease (CVD) risk and particularly concerning women. No previous study on long-term GH therapy in adults with childhood onset (CO) craniopharyngioma was identified.


OBJECTIVE
To investigate CVD risk in adults with CO craniopharyngioma on complete hormone replacement, including long-term GH therapy, and to investigate the impact of disease-related factors on CVD risk.


METHODS
In a cross-sectional study of operated CO craniopharyngiomas (1958-2000) from a defined area of Sweden (2.5 million), we enrolled 42 patients (20 women) with a median age of 28 years (range 17-57) and assessed CVD risk of 20 (4-40) years after first operation. Comparisons were made with matched controls and between patients with tumor growth into the third ventricle (TGTV) versus non-TGTV. GH therapy was 10-12 years in women and men. Results In comparison with controls, both male and female patients had increased body mass index, fat mass, insulin, and leptin levels. Overall, while not significantly increased in male patients, 55-60% of female patients had a medium-high CVD risk, compared with 10-20% in controls. An increased CVD risk (all P<0.05) and higher levels of fat mass and insulin were recorded in the TGTV group versus the non-TGTV group. Late puberty induction and lack of androgens were shown in female patients.


CONCLUSIONS
Adult patients with CO craniopharyngioma, especially those with TGTV, have persistently increased CVD risk. Conventional hormone substitution, including GH, is insufficient to normalize CVD risk, suggesting an important role for irreversible hypothalamic dysfunction.
Holmer
Helene
H
Department of Internal Medicine, Centralsjukhuset, Kristianstad, Lund, Sweden.
Ekman
Bertil
B
Björk
Jonas
J
Nordstöm
Carl-Henrik
CH
Popovic
Vera
V
Siversson
Annbritt
A
Erfurth
Eva-Marie
EM
D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D001823:Body Composition; D015992:Body Mass Index; D002318:Cardiovascular Diseases / Q000097:blood / Q000209:etiology*; D003397:Craniopharyngioma / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D003430:Cross-Sectional Studies; D005260:Female; D020249:Hormone Replacement Therapy / Q000379:methods*; D019382:Human Growth Hormone / Q000008:administration & dosage*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000473:pathology*; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D055815:Young Adult
D007328:Insulin; D020738:Leptin; D019382:Human Growth Hormone